Articles related to SQUAMOUS CELL CARCINOMA

Cosibelimab Safe, Clinically Active in Patients With mCSCC

In Study CK-301-101, the primary efficacy endpoint was objective response rate (complete + partial response, by independent central review), which was 47% (n = 15) in 32 metastatic cutaneous squamous cell carcinoma (mCSCC) patients evaluable for response, including three complete responses and 12 partial responses. The results from the study were presented at the ESMO Congress.

Dermatology September 28th 2020

Tags: SKIN CANCER SQUAMOUS CELL CARCINOMA

FDA Approves Nivolumab for Treatment of Certain Patients With ESCC

Based on the data from the ATTRACTION-3 clinical trial, the FDA approved nivolumab (Opdivo; BMS) for the treatment of patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC) who previously received fluoropyrimidine- and platinum-based chemotherapy.

Gastroenterology June 15th 2020

Tags: CHEMOTHERAPY DEVICE/DRUG APPROVALS IMMUNOTHERAPY SQUAMOUS CELL CARCINOMA

Trending Topics:

Articles related to SQUAMOUS CELL CARCINOMA

Cosibelimab Safe, Clinically Active in Patients With mCSCC

FDA Approves Nivolumab for Treatment of Certain Patients With ESCC

Topics

Sources

The Healthcare Communications Network is owned and operated by IQVIA Inc. Click below to leave this site and continue to IQVIA’s Privacy Choices form

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form